LONDON: Partners Group, one of the largest private markets investment managers globally, has agreed to sell its longstanding stake in PCI Pharma Services in a deal led by Bain Capital and Kohlberg & Company, the firms said on Tuesday.
The transaction, which values PGPE Ltd’s interest in the global contract development and manufacturing organization (CDMO) at approximately €83 million, will see Partners Group reduce its exposure while reinvesting roughly €18 million to retain a minority stake. The deal is expected to close in the second half of 2025, subject to regulatory approvals.
Partners Group originally acquired a majority stake in PCI in 2016, aiming to expand the company’s strategic relevance to the pharmaceutical and life sciences sector. Under its ownership, PCI transformed into a global player, enhancing its clinical trial services and manufacturing capabilities. Kohlberg and Mubadala acquired majority control in 2020, with Partners Group holding a minority stake.
The new ownership consortium plans to deepen PCI’s market position, supported by continued investment in specialized drug development services.
Founded in 2012 and headquartered in Philadelphia, PCI serves biopharma clients by offering end-to-end solutions across the drug lifecycle. The company benefits from long-term industry tailwinds, including rising disease prevalence and increased R&D spending.